Centre for Integrative Physiology, The University of Edinburgh, Edinburgh, UK.
Mol Pain. 2014 Apr 9;10:24. doi: 10.1186/1744-8069-10-24.
Recent evidence has shown that the chemerin receptor 23 (ChemR23) represents a novel inflammatory pain target, whereby the ChemR23 agonists, resolvin E1 and chemerin, can inhibit inflammatory pain hypersensitivity, by a mechanism that involves normalisation of potentiated spinal cord responses. This study has examined the ability of the ChemR23 agonist, chemerin, to modulate synaptic input to lamina I neurokinin 1 receptor expressing (NK1R+) dorsal horn neurons, which are known to be crucial for the manifestation of inflammatory pain.
Whole-cell patch-clamp recordings from pre-identified lamina I NK1R+ neurons, in rat spinal cord slices, revealed that chemerin significantly attenuates capsaicin potentiation of miniature excitatory postsynaptic current (mEPSC) frequency, but is without effect in non-potentiated conditions. In tissue isolated from complete Freund's adjuvant (CFA) treated rats, chemerin significantly reduced the peak amplitude of monosynaptic C-fibre evoked excitatory postsynaptic currents (eEPSCs) in a subset of lamina I NK1R+ neurons, termed chemerin responders. However, chemerin did not alter the peak amplitude of monosynaptic C-fibre eEPSCs in control tissue. Furthermore, paired-pulse recordings in CFA tissue demonstrated that chemerin significantly reduced paired-pulse depression in the subset of neurons classified as chemerin responders, but was without effect in non-responders, indicating that chemerin acts presynaptically to attenuate monosynaptic C-fibre input to a subset of lamina I NK1R+ neurons.
These results suggest that the reported ability of ChemR23 agonists to attenuate inflammatory pain hypersensitivity may in part be due to a presynaptic inhibition of monosynaptic C-fibre input to lamina I NK1R+ neurons and provides further evidence that ChemR23 represents a promising inflammatory pain target.
最近的证据表明,趋化素受体 23(ChemR23)是一种新的炎症性疼痛靶点,趋化素受体 23 激动剂,如 resolvin E1 和趋化素,通过使脊髓反应增强正常化的机制,可抑制炎症性疼痛过敏。本研究检查了趋化素受体 23 激动剂趋化素调节表达神经激肽 1 受体(NK1R+)背角神经元的突触传入的能力,已知这些神经元对炎症性疼痛的表现至关重要。
在大鼠脊髓切片中,从预先鉴定的 lamina I NK1R+神经元进行全细胞膜片钳记录,发现趋化素显著减弱辣椒素对微小兴奋性突触后电流(mEPSC)频率的增强作用,但在未增强的条件下没有作用。在完全弗氏佐剂(CFA)处理的大鼠分离的组织中,趋化素显著降低了 lamina I NK1R+神经元中一部分称为趋化素反应神经元的单突触 C 纤维诱发的兴奋性突触后电流(eEPSC)的峰值幅度。然而,趋化素并未改变对照组织中单突触 C 纤维 eEPSC 的峰值幅度。此外,在 CFA 组织中的成对脉冲记录表明,趋化素显著降低了分类为趋化素反应神经元的亚组的成对脉冲抑制,而在非反应神经元中没有作用,表明趋化素在突触前作用以减弱 lamina I NK1R+神经元的单突触 C 纤维输入。
这些结果表明,趋化素受体 23 激动剂减轻炎症性疼痛过敏的能力可能部分归因于对 lamina I NK1R+神经元的单突触 C 纤维输入的突触前抑制,并进一步证明趋化素受体 23 是一个有前途的炎症性疼痛靶点。